NASDAQ:XBITXBiotech Stock Price, Forecast & News

XBiotech's stock was trading at $10.72 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XBIT stock has increased by 29.1% and is now trading at $13.84. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for XBiotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for XBiotech.

XBiotech is scheduled to release its next quarterly earnings announcement on Thursday, June 4th 2020. View our earnings forecast for XBiotech.

XBiotech Inc (NASDAQ:XBIT) released its earnings results on Tuesday, November, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.15). View XBiotech's earnings history.

2 analysts have issued 1 year price objectives for XBiotech's stock. Their forecasts range from $18.00 to $28.00. On average, they anticipate XBiotech's stock price to reach $23.00 in the next twelve months. This suggests a possible upside of 66.2% from the stock's current price. View analysts' price targets for XBiotech.

News stories about XBIT stock have trended somewhat positive recently, according to InfoTrie Sentiment. The research firm ranks the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. XBiotech earned a coverage optimism score of 0.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the next few days. View the latest news aboutXBiotech.

XBiotech saw a decline in short interest during the month of May. As of May 15th, there was short interest totaling 2,220,000 shares, a decline of 7.5% from the April 30th total of 2,400,000 shares. Based on an average daily trading volume, of 513,200 shares, the days-to-cover ratio is currently 4.3 days. Currently, 16.2% of the shares of the company are short sold. View XBiotech's Current Options Chain.

Some companies that are related to XBiotech include Y-mAbs Therapeutics (YMAB), BELLUS Health (BLUSF), Dicerna Pharmaceuticals (DRNA), Passage Bio (ZNTL), Akcea Therapeutics (AKCA), Amneal Pharmaceuticals (AMRX), Constellation Pharmaceuticals (CNST), CytoDyn (CYDY), Opko Health (OPK), ZEALAND PHARMA/S (ZEAL), Innoviva (INVA), Portola Pharmaceuticals (PTLA), Phoenix Tree (IMAB), Intra-Cellular Therapies (ITCI) and Karyopharm Therapeutics (KPTI). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other XBiotech investors own include Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Cidara Therapeutics (CDTX), Micron Technology (MU), Novavax (NVAX), Ocular Therapeutix (OCUL), Sanofi (SNY), Crispr Therapeutics (CRSP), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

(XBIT) raised $76 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $18.00-$20.00 per share. WR Hambrecht + Co served as the underwriter for the IPO.

XBiotech trades on the NASDAQ under the ticker symbol "XBIT."

XBiotech's stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.47%), Geode Capital Management LLC (0.96%), State Street Corp (0.92%), Jane Street Group LLC (0.49%), Russell Investments Group Ltd. (0.36%) and Nuveen Asset Management LLC (0.21%). Company insiders that own XBiotech stock include Fondation Rennes, Street Financial SA Bay, W Thorpe Mckenzie and W Thorpe Mckenzie. View institutional ownership trends for XBiotech.

XBIT stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Geode Capital Management LLC, Alps Advisors Inc., Squarepoint Ops LLC, Bank of New York Mellon Corp, Morgan Stanley, and Nuveen Asset Management LLC. View insider buying and selling activity for XBiotech.

XBIT stock was purchased by a variety of institutional investors in the last quarter, including Jane Street Group LLC, Balyasny Asset Management LLC, Russell Investments Group Ltd., Paloma Partners Management Co, Alliancebernstein L.P., AQR Capital Management LLC, BNP Paribas Arbitrage SA, and Meeder Asset Management Inc.. Company insiders that have bought XBiotech stock in the last two years include Fondation Rennes, and W Thorpe Mckenzie. View insider buying and selling activity for XBiotech.

Shares of XBIT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XBIT stock can currently be purchased for approximately $13.84.

XBiotech has a market capitalization of $399.28 million. XBiotech employs 56 workers across the globe.

The official website for XBiotech is www.xbiotech.com.

XBiotech's mailing address is 5217 Winnebago Ln, AUSTIN TX, 78744. The biopharmaceutical company can be reached via phone at 512-386-2900 or via email at [email protected]